Journal of Biological Chemistry · 2011 · 36 citations · 15 references
MedicineMolecular BiologyOncologyMolecular Cell BiologyMolecular OncologySignal TransductionCancer Cell SignalingMetastatic Signaling PathwaysOncogenic Signaling PathwaysReceptor Tyrosine Kinase SignalingSignal Transduction In CancerTranscription FactorsNrf2 Pathway ActivationNrf2 Signaling PathwayNrf2-mediated Cytoprotective SignalingReceptor Tyrosine Kinase ActivationRon Receptor Signaling
Recepteur d' origine nantais (RON), a tyrosine kinase receptor, is aberrantly expressed in human tumors and promotes cancer cell invasion. RON receptor activation is also associated with resistance to tamoxifen treatment in breast cancer cells. Nrf2 is a positive regulator of cytoprotective genes. Using chromatin immunoprecipitation (ChIP) and site-directed mutagenesis studies of the RON promoter, we identified Nrf2 as a negative regulator of RON gene expression. High Nrf2 and low RON expression was observed in normal mammary tissue whereas high RON and low or undetectable expression of Nrf2 was observed in breast tumors. The Nrf2 inducer sulforaphane (SFN) as well as ectopic Nrf2 expression or knock-down of the Nrf2 negative regulator keap1, which stabilizes Nrf2, inhibited RON expression and invasion of carcinoma cells. Consequently, our studies identified a novel functional role for Nrf2 as a “repressor” and RON kinase as a molecular target of SFN, which mediates the anti-tumor effects of SFN. These results are not limited to breast cancer cells since the Nrf2 inducer SFN stabilized Nrf2 and inhibited RON expression in carcinoma cells from various tumor types. Recepteur d' origine nantais (RON), a tyrosine kinase receptor, is aberrantly expressed in human tumors and promotes cancer cell invasion. RON receptor activation is also associated with resistance to tamoxifen treatment in breast cancer cells. Nrf2 is a positive regulator of cytoprotective genes. Using chromatin immunoprecipitation (ChIP) and site-directed mutagenesis studies of the RON promoter, we identified Nrf2 as a negative regulator of RON gene expression. High Nrf2 and low RON expression was observed in normal mammary tissue whereas high RON and low or undetectable expression of Nrf2 was observed in breast tumors. The Nrf2 inducer sulforaphane (SFN) as well as ectopic Nrf2 expression or knock-down of the Nrf2 negative regulator keap1, which stabilizes Nrf2, inhibited RON expression and invasion of carcinoma cells. Consequently, our studies identified a novel functional role for Nrf2 as a “repressor” and RON kinase as a molecular target of SFN, which mediates the anti-tumor effects of SFN. These results are not limited to breast cancer cells since the Nrf2 inducer SFN stabilized Nrf2 and inhibited RON expression in carcinoma cells from various tumor types.
15
Minerva Ramos‐Gómez, Mi-Kyoung Kwak, Patrick M. Dolan et al. · Proceedings of the National Academy of Sciences · 2001 · 1.1K citations · Full text
Jong‐Min Lee, Marcus J. Calkins, Yuet Wai Kan et al. · Journal of Biological Chemistry · 2003 · 785 citations · Full text
Changjiang Xu, Mou‐Tuan Huang, Guoxiang Shen et al. · Cancer Research · 2006 · 382 citations · Full text
Medicine, Oncology, Pharmacology +17